DCC4440 |
Rm-133 |
Promising pro-apoptotic agent, showing activity on various cancer cell lines |
|
DCC4441 |
Rm1490 |
Novel MOR agonist |
|
DCC4442 |
Rm-581-fluo |
Novel Fluorescent ER-Tracker dye, showing potent cytotoxic activity on several types of cancer cells, being accumulated into the endoplasmic reticulum (ER) as highlighted by its colocalization |
|
DCC4443 |
Rms-07 |
The first irreversible covalent MPS1 inhibitor, targeting a poorly conserved cysteine in the kinase's hinge region |
|
DCC4444 |
rn-450 |
Potent, reversible, non-carbonyl inhibitor of fatty acid amide hydrolase (FAAH) |
|
DCC4445 |
Rna Ligand Tppc |
Novel potent and specific RNA-binding ligand, targeting riboswitches and other RNAs at proximal subsites |
|
DCC4446 |
Ro 04-5595 Hydrochloride |
Selective antagonist of NMDA receptors NR2B subunits |
|
DCC4447 |
ro 115-1240 |
Selective alpha1A/1L-adrenoceptor partial agonist |
|
DCC4448 |
Ro 25-6981 Benzoate |
Potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit |
|
DCC4449 |
Ro 31-8220 |
Potent protein kinase C (PKC) inhibitor |
|
DCC4450 |
Ro 32-7315 |
ADAM17-selective inhibitor |
|
DCC4451 |
Ro 48-8587 |
Competitive AMPA receptor antagonist |
|
DCC4452 |
Ro 64-5229 |
Selective, non-competitive Metabotropic_glutamate_receptor>mGlu2 antagonist |
|
DCC4453 |
Ro 8-4304 |
Novel NR2B selective, non-competitive, voltage-independent antagonist |
|
DCC4454 |
Ro 8-4304 Hydrochloride |
NMDA receptor antagonist , specifically suppressing the severe autoimmune phenotypes of chs3-2D (chilling sensitive 3, 2D), including the arrested growth morphology and heightened PR (Pathogenesis Related) gene expression |
|
DCC4455 |
Ro-09-4609 |
Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor |
|
DCC4456 |
Ro-09-4879 |
Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor, exhibiting antifungal activity in vivo |
|
DCC4457 |
Ro-23-7553 |
Vitamin D analogue, showing significant in vitro and in vivo antitumor activity. |
|
DCC4458 |
Ro26-4550 Tfa Salt |
Novel reversible inhibitor of interleukin-2 (IL-2) |
|
DCC4459 |
Ro31-4724 |
Dual inhibitor of HDAC and MMP |
|
DCC4460 |
ro3206145 |
Potent and selective inhibitor of the p38 MAPK catalytic domain |
|
DCC4461 |
Ro-363 |
Beta(1) adrenoceptor-selective agonist |
|
DCC4462 |
Ro4432717 |
Novel mGlu2/3 negative allosteric modulator (NAM) |
|
DCC4463 |
Ro4491533 |
Selective negative allosteric modulator of mGlu3 |
|
DCC4464 |
Ro4583298 |
Novel highly potent dual NK1/NK3 receptor antagonist |
|
DCC4465 |
Ro4597014 |
Novel Glucokinase Activator for the Treatment of Type 2 Diabetes |
|
DCC4466 |
Ro5234444 |
Orally active chemokine receptor CCR2 antagonist preventing glomerulosclerosis and renal failure in type 2 diabetes |
|
DCC4467 |
Ro5527239 |
Novel potent, orally available GPBAR1 agonist |
|
DCC4468 |
Ro-57-bpyne |
Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species |
|
DCC4469 |
Ro6800020 |
Potent γ-secretase modulator (GSM) |
|